EZH2: An emerging role in melanoma biology and strategies for targeted therapy

Pigment Cell and Melanoma Research

Volumn 28, Issue 1, 2015, Pages 21-30

  Tiffen, Jessamy ^a   Gallagher, Stuart J ^a   Hersey, Peter ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Epigenetics; EZH2; H3K27me3; Histone methyltransferase; Melanoma; Small molecule inhibitor

Indexed keywords

ENHANCER OF ZESTE HOMOLOG 2 INHIBITOR; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; POLYCOMB REPRESSIVE COMPLEX 2;

ARTICLE; CANCER GROWTH; DEREGULATION; EPIGENETICS; GENE INTERACTION; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; METABOLISM; SKIN NEOPLASMS;

ANIMALS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; POLYCOMB REPRESSIVE COMPLEX 2; SKIN NEOPLASMS;

EID: 84919846786     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12280     Document Type: Article

References (77)

1. Abdel-Rahman, M.H., Pilarski, R., Cebulla, C.M., Massengill, J.B., Christopher, B.N., Boru, G., Hovland, P., and Davidorf, F.H. (2011). Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856-859.
2. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249. doi:10.1038/nmeth0410-248.
3. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C. et al. (2013). Signatures of mutational processes in human cancer. Nature 500, 415-421.
4. Antonysamy, S., Condon, B., Druzina, Z. et al. (2013). Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS ONE 8, 0084147.
5. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., and Schapira, M. (2012). Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400.
6. Asangani, I.A., Harms, P.W., Dodson, L. et al. (2012). Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3, 1011-1025.
7. Bachmann, I.M., Halvorsen, O.J., Collett, K., Stefansson, I.M., Straume, O., Haukaas, S.A., Salvesen, H.B., Otte, A.P., and Akslen, L.A. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268-273.
8. Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837.
9. Beguelin, W., Popovic, R., Teater, M. et al. (2013). EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692.
10. Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., and Weinberg, R.A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507.
11. Bodor, C., Grossmann, V., Popov, N. et al. (2013). EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165-3168.
12. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043.
13. Ceol, C.J., Houvras, Y., Jane-Valbuena, J. et al. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517.
14. Cerami, E., Gao, J., Dogrusoz, U. et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404.
15. Cha, T.-L., Zhou, B.P., Xia, W., Wu, Y., Yang, C.-C., Chen, C.-T., Ping, B., Otte, A.P., and Hung, M.-C. (2005). Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310.
16. Chen, X., He, D., Dong, X.D., Dong, F., Wang, J., Wang, L., Tang, J., Hu, D.N., Yan, D., and Tu, L. (2013). MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 54, 2248-2256.
17. Davidovich, C., Zheng, L., Goodrich, K.J., and Cech, T.R. (2013). Promiscuous RNA binding by Polycomb repressive complex 2. Nat. Struct. Mol. Biol. 20, 1250-1257.
18. Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27.
19. Dawson, M.A., Kouzarides, T., and Huntly, B.J.P. (2012). Targeting epigenetic readers in cancer. N. Engl. J. Med. 367, 647-657.
20. Ezhkova, E., Lien, W.H., Stokes, N., Pasolli, H.A., Silva, J.M., and Fuchs, E. (2011). EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 25, 485-498.
21. Fan, T., Jiang, S., Chung, N., Alikhan, A., Ni, C., Lee, C.C., and Hornyak, T.J. (2011). EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol. Cancer Res. 9, 418-429.
22. Goff, L.A., and Rinn, J.L. (2013). Poly-combing the genome for RNA Nat. Struct. Mol. Biol. 20, 1344-1346 doi: 10.1038/nsmb.2728.
23. Grasso, C.S., Wu, Y.M., Robinson, D.R. et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243.
24. Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A., Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
25. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
26. Holling, T.M., Bergevoet, M.W., Wilson, L., van Eggermond, M.C., Schooten, E., Steenbergen, R.D., Snijders, P.J., Jager, M.J., and van den Elsen, P.J. (2007). A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J. Immunol. 179, 5317-5325.
27. Hou, P., Liu, D., Dong, J., and Xing, M. (2012). The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 11, 286-295.
28. van den Hurk, K., Niessen, H.E., Veeck, J., van den Oord, J.J., van Steensel, M.A., Zur Hausen, A., Van Engeland, M., and Winnepenninckx, V.J. (2012). Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim. Biophys. Acta 1826, 89-102.
29. Jones, R.S., and Gelbart, W.M. (1990). Genetic analysis of the enhancer of zeste locus and its role in gene regulation in Drosophila melanogaster. Genetics 126, 185-199.
30. Kaneko, S., Son, J., Shen, S.S., Reinberg, D., and Bonasio, R. (2013). PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells. Nat. Struct. Mol. Biol. 20, 1258-1264.
31. Kim, W., Bird, G.H., Neff, T., Guo, G., Kerenyi, M.A., Walensky, L.D., and Orkin, S.H. (2013). Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9, 643-650.
32. Knutson, S.K., Wigle, T.J., Warholic, N.M. et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896.
33. Knutson, S.K., Warholic, N.M., Wigle, T.J. et al. (2013). Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. 110, 7922-7927.
34. Knutson, S.K., Kawano, S., Minoshima, Y. et al. (2014). Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor Activity in EZH2 mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 21, 21.
35. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
36. Limm, K., Ott, C., Wallner, S., Mueller, D.W., Oefner, P., Hellerbrand, C., and Bosserhoff, A.K. (2013). Deregulation of protein methylation in melanoma. Eur. J. Cancer 49, 1305-1313.
37. Luo, C., Tetteh, P.W., Merz, P.R. et al. (2013). miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J. Invest. Dermatol. 133, 768-775.
38. MacGregor, S., Montgomery, G.W., Liu, J.Z. et al. (2011). Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43, 1114-1118.
39. Maerker, D.A., Zeschnigk, M., Nelles, J., Lohmann, D.R., Worm, K., Bosserhoff, A.K., Krupar, R., and Jagle, H. (2014). BAP1 germline mutation in two-first grade family members with uveal melanoma. Br. J. Ophthalmol. 98, 224-227.
40. Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, B.D., and Reinberg, D. (2008). Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503-518.
41. McCabe, M.T., Graves, A.P., Ganji, G. et al. (2012a). Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989-2994.
42. McCabe, M.T., Ott, H.M., Ganji, G. et al. (2012b). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112.
43. McHugh, J.B., Fullen, D.R., Ma, L., Kleer, C.G., and Su, L.D. (2007). Expression of polycomb group protein EZH2 in nevi and melanoma. J. Cutan. Pathol. 34, 597-600.
44. Miranda, T.B., Cortez, C.C., Yoo, C.B., Liang, G., Abe, M., Kelly, T.K., Marquez, V.E., and Jones, P.A. (2009). DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588.
45. Morin, R.D., Johnson, N.A., Severson, T.M. et al. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185.
46. Muto, T., Sashida, G., Oshima, M. et al. (2013). Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 210, 2627-2639.
47. Ng, P.C., and Henikoff, S. (2001). Predicting deleterious amino acid substitutions. Genome Res. 11, 863-874.
48. Nicholas, C., Yang, J., Peters, S.B. et al. (2013). PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.). PLoS ONE 8, 0074710.
49. Ntziachristos, P., Tsirigos, A., van Vlierberghe, P. et al. (2012). Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298-301.
50. O'Carroll, D., Erhardt, S., Pagani, M., Barton, S.C., Surani, M.A., and Jenuwein, T. (2001). The polycomb-group gene Ezh2 is required for early mouse development. Mol. Cell. Biol. 21, 4330-4336.
51. O'Meara, M.M., and Simon, J.A. (2012). Inner workings and regulatory inputs that control Polycomb repressive complex 2. Chromosoma 121, 221-234.
52. Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264.
53. Poetsch, M., Dittberner, T., and Woenckhaus, C. (2002). Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. Oncogene 21, 3038-3042.
54. Popovic, R., and Licht, J.D. (2012). Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2, 405-413.
55. Qi, W., Chan, H., Teng, L. et al. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109, 21360-21365.
56. Robinson, G., Parker, M., Kranenburg, T.A. et al. (2012). Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48.
57. Scheuermann, J.C., De Ayala Alonso, A.G., Oktaba, K., Ly-Hartig, N., McGinty, R.K., Fraterman, S., Wilm, M., Muir, T.W., and Muller, J. (2010). Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature, 465, 243-247.
58. Shen, H., and Laird, P.W. (2013). Interplay between the cancer genome and epigenome. Cell 153, 38-55.
59. Shen, X., Liu, Y., Hsu, Y.J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.C., and Orkin, S.H. (2008). EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491-502.
60. Sherr, C.J. (2001). The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2, 731-737.
61. Shi, B., Liang, J., Yang, X. et al. (2007). Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 27, 5105-5119.
62. Simon, J.A., and Lange, C.A. (2008). Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647, 21-29.
63. Sneeringer, C.J., Scott, M.P., Kuntz, K.W., Knutson, S.K., Pollock, R.M., Richon, V.M., and Copeland, R.A. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985.
64. de Souza, C.F., Xander, P., Monteiro, A.C., Silva, A.G., da Silva, D.C., Mai, S., Bernardo, V., Lopes, J.D., and Jasiulionis, M.G. (2012). Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. PLoS ONE 7, 11.
65. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P.L., Karuturi, R.K., Tan, P.B., Liu, E.T., and Yu, Q. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063.
66. Tan, J.Z., Yan, Y., Wang, X.X., Jiang, Y., and Xu, H.E. (2014). EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol. Sin. 35, 161-174.
67. Vire, E., Brenner, C., Deplus, R. et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874.
68. van der Vlag, J., and Otte, A.P. (1999). Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 23, 474-478.
69. Wu, Z.L., Zheng, S.S., Li, Z.M., Qiao, Y.Y., Aau, M.Y., and Yu, Q. (2010). Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 17, 801-810.
70. Wu, H., Zeng, H., Dong, A. et al. (2013). Structure of the catalytic domain of EZH2 reveals conformational plasticity in Cofactor and substrate binding sites and explains oncogenic mutations. PLoS ONE 8, 0083737.
71. Xu, K., Wu, Z.J., Groner, A.C. et al. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465-1469.
72. Yao, S., Zhu, Y., and Chen, L. (2013). Advances in targeting cell surface signalling molecules for immune modulation. Nat. Rev. Drug Discov. 12, 130-146.
73. Yap, D.B., Chu, J., Berg, T. et al. (2011). Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459.
74. Young, M.D., Willson, T.A., Wakefield, M.J., Trounson, E., Hilton, D.J., Blewitt, M.E., Oshlack, A., and Majewski, I.J. (2011). ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res. 39, 7415-7427.
75. Zhang, J., Bardot, E., and Ezhkova, E. (2012). Epigenetic regulation of skin: focus on the Polycomb complex. Cell. Mol. Life Sci. 69, 2161-2172.
76. Zheng, H., Gao, L., Feng, Y., Yuan, L., Zhao, H., and Cornelius, L.A. (2009). Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. Cancer Res. 69, 449-457.
77. Zhou, J., Bi, C., Cheong, L.L., Mahara, S., Liu, S.C., Tay, K.G., Koh, T.L., Yu, Q., and Chng, W.J. (2011). The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118, 2830-2839.